Name | Oxybutynin |
Description | Oxybutynin (Ditropan) is a synthetic anticholinergic agent that is used for treatment of urinary incontinence and overactive bladder syndrome. |
In vitro | In human liver microsomes, Oxybutynin inhibits CYP3A4- and CYP2D6-associated activities (testosterone 6β-hydroxylase and dextromethorphan O-demethylase, respectively).Oxybutynin (30,100 nM) competitively antagonizes acetylcholine-induced contraction. |
In vivo | In human liver microsomes, Oxybutynin inhibits CYP3A4- and CYP2D6-associated activities (testosterone 6β-hydroxylase and dextromethorphan O-demethylase, respectively).Oxybutynin (30,100 nM) competitively antagonizes acetylcholine-induced contraction. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 66 mg/mL (184.6 mM) DMSO : 45 mg/mL (125.88 mM), Sonication is recommended.
|
Keywords | mAChR | Kv channels | urinary incontinence | urinary frequency | urinary urgency | Inhibitor | OAB | Potassium Channel | inhibit | Muscarinic acetylcholine receptor | KcsA | Oxybutynin |
Inhibitors Related | Adiphenine hydrochloride | Minoxidil sulfate | Nanofin | Arecoline hydrobromide | Forskolin | Ribavirin | Adenine | Choline chloride | Propoxur | Indapamide |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |